Skip to content
You are now leaving https://www.ionispharma.com to visit

Ionis Presents New Data from NEURO-TTR Study at European ATTR Amyloidosis Meeting

Significant benefit in quality of life and disease severity endpoints observed in inotersen-treated patients compared to placebo-treated patients Consistent and significant differences observed between inotersen-treated and placebo-treated patients independent of disease stage, types of mutation,